Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[INFLAMMATION AND HEMOCOAGULATION].

Klinicheskaia meditsina·2018
Same author

Comparative assessment of the effectiveness of treatment of pulmonary thromboembolism in elderly patients.

Klinicheskaia meditsina·2018
Same author

[New anticoagulants in clinical practice. Effectiveness and problems].

Klinicheskaia meditsina·2018
Same author

[Non-vitamin K antagonist oral anticoagulants for heart diseases].

Terapevticheskii arkhiv·2017
Same author

[Aleksndr Leonidovich Myasnikov].

Klinicheskaia meditsina·2016
Same author

[ARTERIAL HYPERTENSION: A MODERN VIEW OF THE PROBLEM].

Klinicheskaia meditsina·2015

Related Experiment Video

Updated: Mar 21, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

[ANTICOAGULANTS TODAY].

I N Bokarev

    Klinicheskaia Meditsina
    |May 14, 2016
    PubMed
    Summary

    This review covers modern anti-thrombotic drugs, including heparins, vitamin K antagonists, oral anticoagulants, and thrombolytics, for clinical applications.

    Area of Science:

    • Pharmacology
    • Cardiovascular Medicine
    • Hematology

    Context:

    • Thrombotic disorders pose significant clinical challenges.
    • Effective antithrombotic therapy is crucial for patient outcomes.
    • Advances in drug development necessitate updated clinical guidance.

    Purpose:

    • To review current clinical applications of major antithrombotic drug classes.
    • To provide an overview of heparins, vitamin K antagonists, oral anticoagulants, and thrombolytics.
    • To synthesize modern concepts in antithrombotic therapy.

    Summary:

    • Presents a review of contemporary clinical uses for key antithrombotic agents.
    • Discusses the mechanisms and applications of heparins, vitamin K antagonists (e.g., warfarin), direct oral anticoagulants (DOACs), and thrombolytic therapies.

    More Related Videos

    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
    07:08

    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

    Published on: September 5, 2017

    9.0K
    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
    11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    14.5K

    Related Experiment Videos

    Last Updated: Mar 21, 2026

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
    23:33

    The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

    Published on: February 28, 2012

    84.7K
    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
    07:08

    Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

    Published on: September 5, 2017

    9.0K
    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
    11:17

    Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

    Published on: October 12, 2012

    14.5K
  • Highlights the evolving landscape of anticoagulant and antiplatelet strategies.

    • Impact:

    • Aids clinicians in selecting appropriate antithrombotic agents.
    • Informs evidence-based practice for thrombotic condition management.
    • Contributes to improved patient safety and therapeutic efficacy in anticoagulation.